| Customization: | Available |
|---|---|
| Application: | Internal Medicine |
| Usage Mode: | for Injection |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| PRODUCT NAME: | (New) SUPER GLUTA® (Nicotinic Acid Injection 10mg1ml) |
| STRENGTH: | 1%/1ml 10mg/1ml |
| PACKING DETAILS: | 10 Ampoules /box |
| STORAGE: | Store in a cool and dry place below 25ºC, protected from light. |
| SHELF LIFE: | 36 months |
| REGISTRATION DOSSIERS ARE AVAILABLE. | |
| CONSIGNMENT MANUFACTURING, BRAND OEM/ODM SERVICE IS AVAILABLE. | |
Nicotinamide injection demonstrates remarkable dermatological benefits by enhancing skin barrier function and mitigating signs of aging. As a precursor to NAD+, it boosts cellular energy metabolism in keratinocytes, accelerating the synthesis of ceramides and filaggrin-key components for moisture retention. Clinical studies indicate its efficacy in reducing transepidermal water loss (TEWL) by up to 30%, making it valuable for treating xerosis (pathologically dry skin).
Additionally, its anti-inflammatory properties suppress cytokines like IL-6 and TNF-α, alleviating conditions like acne and rosacea. Topical applications are more common, but systemic administration via injection may benefit severe cases (e.g., post-chemotherapy skin toxicity). A 2022 Journal of Investigative Dermatology study noted 25% improvement in skin elasticity with high-dose nicotinamide regimens.
Nicotinamide injection is a first-line therapy for pellagra, a life-threatening niacin deficiency disease. It rapidly replenishes NAD/NADP pools, reversing the classic triad of dermatitis, diarrhea, and dementia. Unlike nicotinic acid, it avoids vasodilation-induced flushing, making it safer for acute care.
The WHO recommends 300-500 mg/day IV/IM for severe cases, with symptom resolution within 48 hours. A 2020 meta-analysis confirmed 92% efficacy in resolving neurological symptoms when administered early. Contraindications include concurrent isoniazid use (competes for metabolic pathways).
By improving microvascular circulation and reducing oxidative stress, nicotinamide injection aids in managing diabetic peripheral neuropathy (DPN). It preserves neuronal function via NAD+-dependent SIRT1 activation, which mitigates mitochondrial dysfunction.
Trials show 200 mg/day IV for 12 weeks reduces neuropathic pain scores by 40% (Diabetes Care, 2021). However, it's adjunctive to standard therapies (e.g., alpha-lipoic acid). Caution is needed in renal impairment due to potential hyperphosphatemia risk.
Nicotinamide injection mitigates mucositis and dermatitis induced by cancer therapies. It enhances DNA repair via PARP-1 upregulation and reduces radiation-induced fibrosis.
A phase III trial (Lancet Oncology, 2023) demonstrated 50% lower grade 3-4 oral mucositis incidence with prophylactic IV nicotinamide (500 mg/m²). It's often combined with glutamine infusions. Note: Benzyl alcohol-free formulations are critical for pediatric oncology use.
){kind=link}